Linked Life Data

3276038

Source:http://linkedlifedata.com/resource/pubmed/id/3276038

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3276038rdf:typepubmed:Citationlld:pubmed
pubmed-article:3276038lifeskim:mentionsumls-concept:C0013018lld:lifeskim
pubmed-article:3276038lifeskim:mentionsumls-concept:C0034721lld:lifeskim
pubmed-article:3276038lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:3276038lifeskim:mentionsumls-concept:C0005841lld:lifeskim
pubmed-article:3276038lifeskim:mentionsumls-concept:C0022646lld:lifeskim
pubmed-article:3276038lifeskim:mentionsumls-concept:C0450127lld:lifeskim
pubmed-article:3276038lifeskim:mentionsumls-concept:C0178539lld:lifeskim
pubmed-article:3276038lifeskim:mentionsumls-concept:C0277785lld:lifeskim
pubmed-article:3276038lifeskim:mentionsumls-concept:C0035015lld:lifeskim
pubmed-article:3276038lifeskim:mentionsumls-concept:C1882923lld:lifeskim
pubmed-article:3276038lifeskim:mentionsumls-concept:C1548437lld:lifeskim
pubmed-article:3276038lifeskim:mentionsumls-concept:C1280464lld:lifeskim
pubmed-article:3276038lifeskim:mentionsumls-concept:C0444498lld:lifeskim
pubmed-article:3276038lifeskim:mentionsumls-concept:C0332120lld:lifeskim
pubmed-article:3276038lifeskim:mentionsumls-concept:C1292733lld:lifeskim
pubmed-article:3276038pubmed:issue1lld:pubmed
pubmed-article:3276038pubmed:dateCreated1988-2-24lld:pubmed
pubmed-article:3276038pubmed:abstractTextThe effects of preoperative donor-specific blood transfusion (DSBT) on the physiologic, morphologic, and immunologic aspects of allograft responsiveness were evaluated in a rat renal transplant model, using the ACI (RT1a) into PVG (RT1c) high-responder strain combination. Indefinite graft survival (mean greater than 63 days) could be induced by DSBT administration alone. In comparison, animals receiving autologous blood transfusion (ABT) all died within 7 days posttransplantation. As assessed by clearance of inulin and paraaminohippurate, renal allograft function in DSBT-pretreated recipients at 6 days was equivalent to that of isograft recipients, and in contrast to the significant reduction seen in ABT treated rats. Likewise, thromboxane B2 (TXB2) production by ex-vivo-perfused allografts from DSBT-treated recipients was comparable to that of isografts, and significantly lower than that of allografts from ABT-treated rats. A significant inverse correlation was found between renal TXB2 production and inulin clearance. Despite these substantial differences in renal function and eicosanoid metabolism, morphologic evaluation of renal allografts from DSBT-enhanced and ABT-rejecting recipients at comparable time points showed equivalent histologic manifestations of rejection. In addition, immunohistologic labeling of renal allograft sections and fluorescence-activated cell sorter analysis of cells eluted from allografts showed the same phenotype and pattern of infiltrating T cell subsets in both groups. Specific antidonor cytotoxic T lymphocyte precursor (pCTL) frequencies of cells eluted from kidney grafts were equivalent in DSBT and ABT-pretreated animals, and both groups expressed significantly higher (but equivalent) pCTL frequencies in the kidneys than spleens. Comparisons of the lysis of PVG.R1 (RT1.Aa on a PVG background) and ACI targets indicated that cytotoxic responses from effector cells freshly eluted from DSBT and ABT kidneys were primarily directed against allogeneic class I major histocompatibility complex (MHC) specificities, whereas several long term T cell lines generated from 6-day kidney transplants of both groups expressed a predominant W3/25+ (T helper) phenotype and cytotoxic activity against donor specificities other than RT1.Aa class I MHC. Specific antidonor proliferative T lymphocyte (pPTL) precursor frequencies of cells eluted from renal allografts were also equivalent for both DSBT- and ABT-treated recipients, and the range of pPTL frequencies for allograft cell eluates was similar to that in spleens, regardless of the source of the transfusion.(ABSTRACT TRUNCATED AT 400 WORDS)lld:pubmed
pubmed-article:3276038pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3276038pubmed:languageenglld:pubmed
pubmed-article:3276038pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3276038pubmed:citationSubsetIMlld:pubmed
pubmed-article:3276038pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3276038pubmed:statusMEDLINElld:pubmed
pubmed-article:3276038pubmed:monthJanlld:pubmed
pubmed-article:3276038pubmed:issn0041-1337lld:pubmed
pubmed-article:3276038pubmed:authorpubmed-author:SanfilippoFFlld:pubmed
pubmed-article:3276038pubmed:authorpubmed-author:HowellD NDNlld:pubmed
pubmed-article:3276038pubmed:authorpubmed-author:RuizPPlld:pubmed
pubmed-article:3276038pubmed:authorpubmed-author:BaldwinW...lld:pubmed
pubmed-article:3276038pubmed:authorpubmed-author:KlotmanP EPElld:pubmed
pubmed-article:3276038pubmed:authorpubmed-author:CoffmanT MTMlld:pubmed
pubmed-article:3276038pubmed:authorpubmed-author:ScroggsM WMWlld:pubmed
pubmed-article:3276038pubmed:authorpubmed-author:StraznickasJJlld:pubmed
pubmed-article:3276038pubmed:issnTypePrintlld:pubmed
pubmed-article:3276038pubmed:volume45lld:pubmed
pubmed-article:3276038pubmed:ownerNLMlld:pubmed
pubmed-article:3276038pubmed:authorsCompleteYlld:pubmed
pubmed-article:3276038pubmed:pagination1-7lld:pubmed
pubmed-article:3276038pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:3276038pubmed:meshHeadingpubmed-meshheading:3276038-...lld:pubmed
pubmed-article:3276038pubmed:meshHeadingpubmed-meshheading:3276038-...lld:pubmed
pubmed-article:3276038pubmed:meshHeadingpubmed-meshheading:3276038-...lld:pubmed
pubmed-article:3276038pubmed:meshHeadingpubmed-meshheading:3276038-...lld:pubmed
pubmed-article:3276038pubmed:meshHeadingpubmed-meshheading:3276038-...lld:pubmed
pubmed-article:3276038pubmed:meshHeadingpubmed-meshheading:3276038-...lld:pubmed
pubmed-article:3276038pubmed:meshHeadingpubmed-meshheading:3276038-...lld:pubmed
pubmed-article:3276038pubmed:meshHeadingpubmed-meshheading:3276038-...lld:pubmed
pubmed-article:3276038pubmed:meshHeadingpubmed-meshheading:3276038-...lld:pubmed
pubmed-article:3276038pubmed:meshHeadingpubmed-meshheading:3276038-...lld:pubmed
pubmed-article:3276038pubmed:meshHeadingpubmed-meshheading:3276038-...lld:pubmed
pubmed-article:3276038pubmed:meshHeadingpubmed-meshheading:3276038-...lld:pubmed
pubmed-article:3276038pubmed:meshHeadingpubmed-meshheading:3276038-...lld:pubmed
pubmed-article:3276038pubmed:meshHeadingpubmed-meshheading:3276038-...lld:pubmed
pubmed-article:3276038pubmed:meshHeadingpubmed-meshheading:3276038-...lld:pubmed
pubmed-article:3276038pubmed:year1988lld:pubmed
pubmed-article:3276038pubmed:articleTitleEvidence that pretransplant donor blood transfusion prevents rat renal allograft dysfunction but not the in situ cellular alloimmune or morphologic manifestations of rejection.lld:pubmed
pubmed-article:3276038pubmed:affiliationDepartment of Pathology, Duke University Medical Center, Durham, North Carolina 27710.lld:pubmed
pubmed-article:3276038pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3276038pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:3276038pubmed:publicationTypeResearch Support, U.S. Gov't, Non-P.H.S.lld:pubmed
pubmed-article:3276038pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed